Study Details
A study to assess the safety and efficacy of Prograf and MR4 in liver transplant recipients
This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
Clinicaltrials.gov ID
The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
Astellas Study ID
The unique identification code given by the study sponsor.
MR-05-02-KOR
EudraCT ID
The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).
N/A
Condition
Liver Transplants
Phase
These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.
Phase 3
Age
18 Years - N/A
Sex
Female & Male
Product
N/A
Type
A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Interventional
Trial Dates
Feb 2006 - Jun 2008
Masking
None (Open Label)
Enrollment number
74
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de novo Liver Transplant Recipients
Study summary
Study documents
Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study to assess the safety and efficacy of Prograf and MR4 in liver transplant recipients? Contact us by filling our your information to the right and we’ll respond to you.